A new reliable and valid neuropathy measurement tool, in the form of a questionnaire was developed as an easy way to quantify and treat neuropathy symptoms in cancer patients.
Most of the roughly 15.5 million cancer survivors in the U.S. receive chemotherapy, and roughly 65 percent develop some degree of the chemotherapy-induced nerve damage known as peripheral neuropathy.
Peripheral Neuropathy
Peripheral neuropathy is a condition that causes weakness, numbness and pain, especially in the limbs as a result of damage to the peripheral nerves.
Advertisement
‘Neuropathy measurement tool, a questionnaire can be used in the identification, diagnosis and treatment of neuropathy symptoms in cancer patients.’
Tweet it Now
Peripheral neuropathy simply means nerves outside of the brain, and spinal cord is affected, and symptoms include numbness and tingling in extremities, and in about 30 percent of patients, pain.
Neuropathy can drastically diminish the quality of life--and in extreme cases, may necessitate chemotherapy dose reductions.
Unfortunately, neuropathy often goes underreported and untreated, said Ellen Lavoie Smith, associate professor at the University of Michigan School of Nursing. This happens because clinicians and researchers don't have a valid, standardized way to measure symptoms or the effectiveness of neuropathy treatments. Right now, the drug Cymbalta (duloxetine) is the only drug FDA-approved to treat painful neuropathy symptoms.
![First Chemotherapy Drug to Prevent Neuropathy]( "First Chemotherapy Drug to Prevent Neuropathy")
New neuropathic pain molecule discovered that may prevent the onset of peripheral neuropathy that usually follows chemotherapy treatment in cancer patients.
Some doctors and nurses ask patients about neuropathy, or whether they have symptoms of numbness and tingling, and others don't.
"If we don't have a reliable measurement tool, we can't know if the interventions are effective or not," said Smith.
"Historically, it's possible that we've discounted treatments and said they are ineffective based on poor measurements."
Smith's lab wanted to find a better way to quantify neuropathy symptoms and treatment efficacy.
"The ultimate goal is to use a measurement tool in research and clinical settings that have been thoroughly tested and found to be reliable and valid. We believe we have that now," she said.
The neuropathy measurement tool Smith examined in her research is a questionnaire developed in Europe and owned by an international research network. It's a patient-reported outcome measure called the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Chemotherapy-Induced Peripheral Neuropathy Scale (QLQ-CIPN20).37.
Findings suggest that with minor revisions, it could be universally adopted in both labs and doctors' offices to help researchers and clinicians quantify and treat this painful condition.
Six previous publications provide evidence supporting the tool's effectiveness. However, two studies provide conflicting evidence about the instrument's validity, and another study suggests that minor revisions could improve that.
Some researchers use the questionnaire now, but for a variety of reasons it's not used in the clinic with cancer patients, said Smith.
"The next step is for researchers worldwide to consider using the same tool because then the results from one researcher can be compared directly with results from the next," she said.
Source: Eurekalert
Unfortunately, neuropathy often goes underreported and untreated, said Ellen Lavoie Smith, associate professor at the University of Michigan School of Nursing. This happens because clinicians and researchers don't have a valid, standardized way to measure symptoms or the effectiveness of neuropathy treatments. Right now, the drug Cymbalta (duloxetine) is the only drug FDA-approved to treat painful neuropathy symptoms.
First Chemotherapy Drug to Prevent Neuropathy
New neuropathic pain molecule discovered that may prevent the onset of peripheral neuropathy that usually follows chemotherapy treatment in cancer patients.
Advertisement
Some doctors and nurses ask patients about neuropathy, or whether they have symptoms of numbness and tingling, and others don't.
"If we don't have a reliable measurement tool, we can't know if the interventions are effective or not," said Smith.
"Historically, it's possible that we've discounted treatments and said they are ineffective based on poor measurements."
Smith's lab wanted to find a better way to quantify neuropathy symptoms and treatment efficacy.
"The ultimate goal is to use a measurement tool in research and clinical settings that have been thoroughly tested and found to be reliable and valid. We believe we have that now," she said.
The neuropathy measurement tool Smith examined in her research is a questionnaire developed in Europe and owned by an international research network. It's a patient-reported outcome measure called the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Chemotherapy-Induced Peripheral Neuropathy Scale (QLQ-CIPN20).37.
Findings suggest that with minor revisions, it could be universally adopted in both labs and doctors' offices to help researchers and clinicians quantify and treat this painful condition.
Six previous publications provide evidence supporting the tool's effectiveness. However, two studies provide conflicting evidence about the instrument's validity, and another study suggests that minor revisions could improve that.
Some researchers use the questionnaire now, but for a variety of reasons it's not used in the clinic with cancer patients, said Smith.
"The next step is for researchers worldwide to consider using the same tool because then the results from one researcher can be compared directly with results from the next," she said.
Source: Eurekalert
New Treatment For Peripheral Neuropathy
Peripheral Neuropathy is the damage that occurs to the peripheral nervous system. Blocking the neuron signaling pathway can provide treatment.
Advertisement
 Neurofeedback Could Reduce Chemotherapy-Induced Neuropathy PainNeurofeedback or functional brain training shows promise in reducing chemotherapy-induced peripheral neuropathy in cancer survivors. | Advertisement
|
Advertisement
Recommended Reading
Latest Cancer News
The mission of Axiom Space incorporated numerous experiments focusing on human stem cell aging, inflammation, and cancer within the laboratory situated in the low Earth orbit.
Providing a sustained supply of hydrogen sulfide to cancer cells, could be a remodeling strategy to improve photothermal therapy efficacy while minimizing side effects.
Colon cancer's hidden link revealed in microbiome study.
Breast cancer patients in the obese or overweight category can greatly benefit from a telephone-based weight management program in achieving significant weight loss.
A new study assessed the association of cigarette smoking and vaping on cancer-related symptom burden (fatigue, pain, emotional problems) and quality of life.